nCVTs: a hybrid smart tumour targeting platform
A hybrid drug delivery platform involving the fusion of cell membranes from U937 monocytes and synthetic lipids to create nano-cell vesicle technology systems (nCVTs) is designed. nCVTs are engineered for a targeted approach towards tumour sites by preserving key surface proteins from U937 monocytes, while being amendable to functionalization and loading due to their liposomal components.
- Source:
- Tags:
Backlinks
These are the other notes that link to this one.
Nothing links here, how did you reach this page then?
Comment
Share your thoughts on this note. Comments are not public, they are
messages sent directly to my inbox.
Aquiles Carattino
This note you are reading is part
of my digital garden. Follow the
links to learn more, and remember that these notes evolve over time. After all,
this website is not a
blog.